Elizabeth Plimack MD
@erplimackmd.bsky.social
Deputy Director at Fox Chase Cancer Center. Philadelphia USA.
Professor GU Medical Oncology.
Views Mine. COI: https://coi.asco.org/share/3BX-RW4D/Elizabeth%20Plimack
Professor GU Medical Oncology.
Views Mine. COI: https://coi.asco.org/share/3BX-RW4D/Elizabeth%20Plimack
Pinned
Join the conversation on all things #bladdercancer #kidneycancer #prostatecancer and help grow the GU Oncology Starter Pack go.bsky.app/6NdMXmY
How Trump’s Medical Research Cuts Would Hit Colleges and Hospitals in Every State www.nytimes.com/interactive/...
How Trump’s Medical Research Cuts Would Hit Colleges and Hospitals in Every State
Changes to a key funding formula will reduce research grants at hospitals and universities by billions — and may discourage future research.
www.nytimes.com
February 16, 2025 at 9:56 AM
How Trump’s Medical Research Cuts Would Hit Colleges and Hospitals in Every State www.nytimes.com/interactive/...
Reposted by Elizabeth Plimack MD
Exploring the burden of cancer in metastatic renal cell carcinoma (mRCC) 📊🧬 This study sheds light on the impact of mRCC on patients & healthcare systems. Don’t miss these key insights @ascocancer.bsky.social #GU25!
February 15, 2025 at 6:39 PM
Exploring the burden of cancer in metastatic renal cell carcinoma (mRCC) 📊🧬 This study sheds light on the impact of mRCC on patients & healthcare systems. Don’t miss these key insights @ascocancer.bsky.social #GU25!
Reposted by Elizabeth Plimack MD
#MattGalsky updating results of #NIAGARA - great to see pathologic complete responses from neoadj gem-cis-durvalumab — durva improves disease free & overall survival even in those w pathCR. @ascocancer.bsky.social #GU25
February 14, 2025 at 4:51 PM
#MattGalsky updating results of #NIAGARA - great to see pathologic complete responses from neoadj gem-cis-durvalumab — durva improves disease free & overall survival even in those w pathCR. @ascocancer.bsky.social #GU25
Reposted by Elizabeth Plimack MD
On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social
February 15, 2025 at 5:23 PM
On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social
Reposted by Elizabeth Plimack MD
Why is funding NIH so important? Listen to the Good News About Cancer w/ @charlesryanmd.bsky.social @mskcancercenter.bsky.social @drkarenknudsen.bsky.social & Dr. Morgans. Also amazing news about decline in lung cancer in Puerto Rico b/c of public health measures! podcasts.apple.com/us/podcast/4...
4.75 Million Lives Saved, and Counting
Podcast Episode · The Good News About Cancer · 02/11/2025 · 23m
podcasts.apple.com
February 15, 2025 at 9:37 PM
Why is funding NIH so important? Listen to the Good News About Cancer w/ @charlesryanmd.bsky.social @mskcancercenter.bsky.social @drkarenknudsen.bsky.social & Dr. Morgans. Also amazing news about decline in lung cancer in Puerto Rico b/c of public health measures! podcasts.apple.com/us/podcast/4...
Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...
February 15, 2025 at 3:36 PM
Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...
Reposted by Elizabeth Plimack MD
@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25
February 14, 2025 at 5:07 PM
@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25
Reposted by Elizabeth Plimack MD
Watching #BCR session @asco #GU25 it is very clear there is a drive to treat #BCR asap esp w/+ #PSMA
But there is no data supporting a curative strategy & in that context deferring therapy max’ing #QOL is quite reasonable given JHU MFS data below
ascopubs.org/doi/10.1200/...
But there is no data supporting a curative strategy & in that context deferring therapy max’ing #QOL is quite reasonable given JHU MFS data below
ascopubs.org/doi/10.1200/...
February 13, 2025 at 10:46 PM
Reposted by Elizabeth Plimack MD
Announcing the ASCO Genitourinary Cancers Symposium Featured Voices! Follow along for a range of expert insights and join the conversation using the official hashtag: #GU25
Not yet registered? There’s still time to join us in person or online: brnw.ch/21wQAYk
Not yet registered? There’s still time to join us in person or online: brnw.ch/21wQAYk
February 10, 2025 at 4:00 PM
Announcing the ASCO Genitourinary Cancers Symposium Featured Voices! Follow along for a range of expert insights and join the conversation using the official hashtag: #GU25
Not yet registered? There’s still time to join us in person or online: brnw.ch/21wQAYk
Not yet registered? There’s still time to join us in person or online: brnw.ch/21wQAYk
Reposted by Elizabeth Plimack MD
As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
February 10, 2025 at 11:22 PM
As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Elizabeth Plimack MD
SUPER BOWL CHAMPIONS!
THIS ONE’S FOR YOU PHILLY!
THIS ONE’S FOR YOU PHILLY!
February 10, 2025 at 3:45 AM
SUPER BOWL CHAMPIONS!
THIS ONE’S FOR YOU PHILLY!
THIS ONE’S FOR YOU PHILLY!
Reposted by Elizabeth Plimack MD
Trump & Musk are making massive cuts to the National Institutes of Health.
I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.
I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.
February 8, 2025 at 11:16 PM
Trump & Musk are making massive cuts to the National Institutes of Health.
I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.
I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.
Reposted by Elizabeth Plimack MD
Both ERA Commons and NIH Reporter are currently unavailable.
February 9, 2025 at 2:01 AM
Both ERA Commons and NIH Reporter are currently unavailable.
Reposted by Elizabeth Plimack MD
🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25:
- Bladder Ca
- Prostate Ca
- RCC
*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25
#OncSky #MedSky #gusm #Oncology #Cancer #CanSky
- Bladder Ca
- Prostate Ca
- RCC
*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25
#OncSky #MedSky #gusm #Oncology #Cancer #CanSky
February 6, 2025 at 11:23 PM
🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25:
- Bladder Ca
- Prostate Ca
- RCC
*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25
#OncSky #MedSky #gusm #Oncology #Cancer #CanSky
- Bladder Ca
- Prostate Ca
- RCC
*Join us LIVE*
📅 Date: Feb 12, 2025
⏰ Time: 6:00-8:00PM
📝 bit.ly/guaio25
#OncSky #MedSky #gusm #Oncology #Cancer #CanSky
Reposted by Elizabeth Plimack MD
In the ESOPEC trial, researchers evaluated whether perioperative chemotherapy improves overall survival as compared with preoperative chemoradiotherapy in patients with resectable esophageal adenocarcinoma. Full trial results and Plain Language Summary: nej.md/4apWlo5
#MedSky #Oncology
#MedSky #Oncology
January 26, 2025 at 8:17 PM
In the ESOPEC trial, researchers evaluated whether perioperative chemotherapy improves overall survival as compared with preoperative chemoradiotherapy in patients with resectable esophageal adenocarcinoma. Full trial results and Plain Language Summary: nej.md/4apWlo5
#MedSky #Oncology
#MedSky #Oncology
Reposted by Elizabeth Plimack MD
Hello, #MedSky community! We’re excited to begin our Bluesky journey.
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
December 6, 2024 at 8:24 PM
Hello, #MedSky community! We’re excited to begin our Bluesky journey.
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:
Reposted by Elizabeth Plimack MD
FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma @fda.gov #oncology
www.onclive.com/view/fda-gra...
www.onclive.com/view/fda-gra...
FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma
The FDA has granted priority review to belzutifan for advanced pheochromocytoma and paraganglioma.
www.onclive.com
January 27, 2025 at 4:14 PM
FDA Grants Priority Review to Belzutifan for Advanced Pheochromocytoma and Paraganglioma @fda.gov #oncology
www.onclive.com/view/fda-gra...
www.onclive.com/view/fda-gra...
Reposted by Elizabeth Plimack MD
Hello out there scientists. If you're having meetings or grants or anything else impacted by freeze of NSF meetings, please feel free to reach out to me to share your story.
Signal: thealexknapp.79
Email: aknapp@forbes.com
Signal: thealexknapp.79
Email: aknapp@forbes.com
January 27, 2025 at 4:21 PM
Hello out there scientists. If you're having meetings or grants or anything else impacted by freeze of NSF meetings, please feel free to reach out to me to share your story.
Signal: thealexknapp.79
Email: aknapp@forbes.com
Signal: thealexknapp.79
Email: aknapp@forbes.com
Reposted by Elizabeth Plimack MD
🎉 EMA celebrates its 3️⃣0️⃣th anniversary highlighting its evolving role at the centre of the EU assessing & authorising safe, high-quality medicines for 450 million people & countless animals in Europe.
Learn more about EMA’s key achievements over the past 30 years: www.ema.europa.eu/en/news/ema-...
Learn more about EMA’s key achievements over the past 30 years: www.ema.europa.eu/en/news/ema-...
EMA celebrates 30 years of progress in science and medicines in the European Union | European Medicines Agency (EMA)
Agency marks milestone highlighting its changing role in Europe
www.ema.europa.eu
January 27, 2025 at 2:04 PM
🎉 EMA celebrates its 3️⃣0️⃣th anniversary highlighting its evolving role at the centre of the EU assessing & authorising safe, high-quality medicines for 450 million people & countless animals in Europe.
Learn more about EMA’s key achievements over the past 30 years: www.ema.europa.eu/en/news/ema-...
Learn more about EMA’s key achievements over the past 30 years: www.ema.europa.eu/en/news/ema-...
Reposted by Elizabeth Plimack MD
This is huge.
The European equivalent to the FDA has said enough to the propaganda machine X.
Others will follow.
#medsky #oncosky
www.reuters.com/world/europe...
The European equivalent to the FDA has said enough to the propaganda machine X.
Others will follow.
#medsky #oncosky
www.reuters.com/world/europe...
EU medicines agency quits X, moves to Bluesky
The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media platform that some have criticised for its content.
www.reuters.com
January 27, 2025 at 10:39 PM
This is huge.
The European equivalent to the FDA has said enough to the propaganda machine X.
Others will follow.
#medsky #oncosky
www.reuters.com/world/europe...
The European equivalent to the FDA has said enough to the propaganda machine X.
Others will follow.
#medsky #oncosky
www.reuters.com/world/europe...
Reposted by Elizabeth Plimack MD
The clearest sign of intellectual chemistry isn’t agreeing with someone. It’s enjoying your disagreements with them.
Harmony is not the combination of identical sounds. It’s the pleasing arrangement of different tones, voices, or instruments.
Creative tension makes beautiful music.
Harmony is not the combination of identical sounds. It’s the pleasing arrangement of different tones, voices, or instruments.
Creative tension makes beautiful music.
January 26, 2025 at 6:37 PM
The clearest sign of intellectual chemistry isn’t agreeing with someone. It’s enjoying your disagreements with them.
Harmony is not the combination of identical sounds. It’s the pleasing arrangement of different tones, voices, or instruments.
Creative tension makes beautiful music.
Harmony is not the combination of identical sounds. It’s the pleasing arrangement of different tones, voices, or instruments.
Creative tension makes beautiful music.
Reposted by Elizabeth Plimack MD
Creating a bladder & kidney cancer starter pack of friends and colleagues here in @bsky.app!
Please comment if you want to be added!
bsky.app/start/did:pl...
@pgrivasmdphd.bsky.social @drchoueiri.bsky.social @erplimackmd.bsky.social @davidaggen.bsky.social @pcvblack.bsky.social
Please comment if you want to be added!
bsky.app/start/did:pl...
@pgrivasmdphd.bsky.social @drchoueiri.bsky.social @erplimackmd.bsky.social @davidaggen.bsky.social @pcvblack.bsky.social
January 23, 2025 at 9:21 PM
Creating a bladder & kidney cancer starter pack of friends and colleagues here in @bsky.app!
Please comment if you want to be added!
bsky.app/start/did:pl...
@pgrivasmdphd.bsky.social @drchoueiri.bsky.social @erplimackmd.bsky.social @davidaggen.bsky.social @pcvblack.bsky.social
Please comment if you want to be added!
bsky.app/start/did:pl...
@pgrivasmdphd.bsky.social @drchoueiri.bsky.social @erplimackmd.bsky.social @davidaggen.bsky.social @pcvblack.bsky.social
Reposted by Elizabeth Plimack MD
Roughly 6,000 readers answered our poll, with many declaring that Bluesky was nicer, kinder and less antagonistic to science than X
https://go.nature.com/42tH8Ai
https://go.nature.com/42tH8Ai
Bluesky’s science takeover: 70% of Nature poll respondents use platform
Roughly 6,000 readers answered our poll, with many declaring that Bluesky was nicer, kinder and less antagonistic to science than X.
go.nature.com
January 24, 2025 at 11:52 AM
Roughly 6,000 readers answered our poll, with many declaring that Bluesky was nicer, kinder and less antagonistic to science than X
https://go.nature.com/42tH8Ai
https://go.nature.com/42tH8Ai